The Open Pharma Revolution: A Strategic Deconstruction of Collaborative Drug Discovery Business Models
A deep-dive pillar page for pharma/biotech IP teams, R&D leads, and institutional investors. Part 1: The R&D Productivity Crisis — […]
The $300 Billion Patent Cliff Playbook: Formulary Management, Generic Entry Timing, and IP Strategy for Payers and Analysts
Why Formulary Management Is Now an IP Discipline The pharmaceutical formulary started its modern life as an administrative cost control
America Pays 3x More for the Same Drug: Patent Thickets, PBM Rebate Walls, and the IRA’s Real Impact on Pharma Strategy
The 80/80 Paradox: What the Numbers Actually Say The U.S. pharmaceutical market runs on a structural contradiction that no other
Dunking on the Pharma Industry: An In-Depth Analysis of Mark Cuban’s War on Drug Prices
The United States pharmaceutical market operates within a network of opaque intermediaries that disconnect manufacturing costs from patient expenditures. Billionaire
Dunking on the Pharma Industry: An In-Depth Analysis of Mark Cuban’s War on Drug Prices Read Post »
Pharma Patent Defense: The Complete Strategy Playbook for IP Teams and Portfolio Managers
1. Why Patent Defense Is a Corporate Strategy Problem, Not a Legal One Patent defense gets handed to legal teams.
How Smarter API Manufacturing Is Dismantling Big Pharma’s Cost Moat: A Technical, IP, and Investment Deep Dive
1. Executive Summary The pharmaceutical industry’s API manufacturing layer is undergoing a structural break, not an upgrade cycle. The convergence
Drug Patent Challenges: Win the Market, Not Just the Lawsuit
A deep-dive for pharma IP teams, portfolio managers, and institutional investors on the strategies, IP valuations, and commercial mechanics that
Drug Patent Challenges: Win the Market, Not Just the Lawsuit Read Post »
Biomedical Business Continuity: Build Resilience or Lose Market Share
The biopharma industry has spent decades optimizing for efficiency. Lean supply chains, single-source API relationships, centralized cell storage, and just-in-time
Biomedical Business Continuity: Build Resilience or Lose Market Share Read Post »
How to own a Market you Don’t Own: Market Access Strategies Post-Drug Patent Expiration
Own the Market After Your Patent Dies A technical deep dive for pharma IP teams, portfolio managers, R&D leads, and
How to own a Market you Don’t Own: Market Access Strategies Post-Drug Patent Expiration Read Post »
